CHA Biotech

Cord blood bank that stores cord blood at minus 196°C and supports transplants through Bundang CHA Hospital.

U.S. subsidiary with a cell and gene therapy CDMO facility in College Station, Texas, producing lentiviral and adeno-associated virus vectors; in September 2026 it extended its services to recombinant protein process development.

Platform combining a mesenchymal stem cell line (CHAMS) and gene-enhanced cells (CHAGE); the lead candidate is CHAGE-201 for idiopathic pulmonary fibrosis. In August 2026 it was selected for the government K-HERO programme (3.5 years, KRW 3.15 billion).

Allogeneic umbilical cord-derived mesenchymal stem cell candidate for chronic low back pain caused by degenerative lumbar discs.

Embryonic stem cell-derived retinal pigment epithelium candidate for macular degeneration and Stargardt disease; licensed to the Astellas Institute for Regenerative Medicine in March 2023 in a deal worth USD 32 million.

Reported first-half 2026 consolidated revenue of KRW 646.1 billion, up 7% year on year, citing growth in its U.S., Australian, Singaporean and Japanese healthcare businesses and the consolidation of Kakao Healthcare and CHA AI Healthcare.

Selected for the Ministry of Science and ICT 2026 K-HERO programme, receiving KRW 3.15 billion over 3.5 years to build CMC systems and run preclinical safety studies for the CHAMS and CHAGE platform and the idiopathic pulmonary fibrosis candidate CHAGE-201.

Selected as a joint research institution in the Ministry of Science and ICT K-CGTAP project led by Bundang CHA Hospital (about KRW 13.7 billion in total, April 2026 to December 2030), where it will develop and validate quality analysis methods for cell therapies.

U.S. subsidiary Matica Biotechnology took on process optimization for Bondwell Technologies' next-generation protein materials, extending its cell and gene therapy process development capabilities into recombinant proteins.